NO20042620L - Belagte partikulaere cefuroxim axetil-blandinger - Google Patents

Belagte partikulaere cefuroxim axetil-blandinger

Info

Publication number
NO20042620L
NO20042620L NO20042620A NO20042620A NO20042620L NO 20042620 L NO20042620 L NO 20042620L NO 20042620 A NO20042620 A NO 20042620A NO 20042620 A NO20042620 A NO 20042620A NO 20042620 L NO20042620 L NO 20042620L
Authority
NO
Norway
Prior art keywords
cefuroxime axetil
mixtures
coated particulate
particulate cefuroxime
masked
Prior art date
Application number
NO20042620A
Other languages
English (en)
Other versions
NO335273B1 (no
Inventor
Matilde Ibanez Fernandez
Emilio Sanz Garriz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20042620L publication Critical patent/NO20042620L/no
Publication of NO335273B1 publication Critical patent/NO335273B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
NO20042620A 2001-11-23 2004-06-22 Blanding omfattende cefuroxim axetil i partikulær form samt farmasøytisk blanding for oral administrering NO335273B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23
PCT/EP2002/013150 WO2003043638A1 (en) 2001-11-23 2002-11-21 Coated particulate cefuroxime axetil compositions

Publications (2)

Publication Number Publication Date
NO20042620L true NO20042620L (no) 2004-06-22
NO335273B1 NO335273B1 (no) 2014-11-03

Family

ID=8183502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042620A NO335273B1 (no) 2001-11-23 2004-06-22 Blanding omfattende cefuroxim axetil i partikulær form samt farmasøytisk blanding for oral administrering

Country Status (34)

Country Link
US (1) US20030161888A1 (no)
EP (1) EP1446126B1 (no)
JP (1) JP3497503B2 (no)
KR (1) KR100979328B1 (no)
CN (1) CN1297274C (no)
AT (1) ATE473006T1 (no)
AU (2) AU2002302147B2 (no)
BE (2) BE1014078A6 (no)
BR (1) BR0204767A (no)
CA (1) CA2408198C (no)
CH (1) CH693982A5 (no)
CO (1) CO5580783A2 (no)
CY (1) CY1110778T1 (no)
CZ (1) CZ12993U1 (no)
DE (3) DE60236952D1 (no)
DK (1) DK1446126T3 (no)
ES (2) ES2201932B2 (no)
FR (1) FR2832635B1 (no)
GB (1) GB2383536B (no)
GR (1) GR1004522B (no)
HR (2) HRP20020924A2 (no)
HU (1) HUP0204026A3 (no)
IL (2) IL161972A0 (no)
IT (1) ITMI20022470A1 (no)
MX (1) MXPA02011561A (no)
NO (1) NO335273B1 (no)
NZ (1) NZ533092A (no)
PL (1) PL205325B1 (no)
PT (1) PT1446126E (no)
RU (1) RU2241460C2 (no)
SI (1) SI1446126T1 (no)
TR (1) TR200202559A2 (no)
WO (1) WO2003043638A1 (no)
ZA (1) ZA200209473B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2005107713A2 (en) 2004-05-11 2005-11-17 Egalet A/S Swellable dosage form comprising gellan gum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) * 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术(石家庄)有限公司 一种微囊化头孢呋辛酯的药物组合物
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
WO2011067667A2 (en) 2009-12-02 2011-06-09 Eurand Pharmaceuticals Limited Fexofenadine microcapsules and compositions containing them
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
WO2011139254A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical formulations compising cefuroxime axetil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2741750A1 (en) * 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
JP6200893B2 (ja) * 2011-10-31 2017-09-20 ノバルティス アーゲー パゾパニブ製剤
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
DE69332801T2 (de) * 1992-11-30 2004-01-29 Kv Pharm Co Geschmacksmaskierte pharmazeutische substanzen
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
US6190591B1 (en) * 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
CN1421206A (zh) 2003-06-04
CZ12993U1 (cs) 2003-02-10
PL357259A1 (en) 2003-06-02
GB2383536A (en) 2003-07-02
GR1004522B (el) 2004-04-06
CH693982A5 (de) 2004-05-28
HUP0204026A3 (en) 2004-09-28
HUP0204026A2 (hu) 2003-08-28
ES2201932B2 (es) 2005-03-16
CA2408198A1 (en) 2003-02-02
JP3497503B2 (ja) 2004-02-16
WO2003043638A1 (en) 2003-05-30
BR0204767A (pt) 2003-09-16
GB2383536B (en) 2003-11-19
DK1446126T3 (da) 2010-10-11
CO5580783A2 (es) 2005-11-30
DE10254412A1 (de) 2003-06-12
AU2002338950A1 (en) 2003-06-10
GR20020100506A (el) 2003-07-16
DE60236952D1 (de) 2010-08-19
RU2241460C2 (ru) 2004-12-10
PT1446126E (pt) 2010-09-24
JP2003160493A (ja) 2003-06-03
NZ533092A (en) 2006-02-24
CY1110778T1 (el) 2015-06-10
US20030161888A1 (en) 2003-08-28
GB0227215D0 (en) 2002-12-24
CA2408198C (en) 2004-03-09
DE20218068U1 (de) 2003-03-27
FR2832635B1 (fr) 2006-04-21
CN1297274C (zh) 2007-01-31
EP1446126B1 (en) 2010-07-07
PL205325B1 (pl) 2010-04-30
FR2832635A1 (fr) 2003-05-30
TR200202559A2 (tr) 2003-06-23
NO335273B1 (no) 2014-11-03
KR20050044590A (ko) 2005-05-12
EP1446126A1 (en) 2004-08-18
ZA200209473B (en) 2003-06-10
HRP20020923A2 (en) 2003-10-31
ES2201932A1 (es) 2004-03-16
ITMI20022470A1 (it) 2003-05-24
ES2347536T3 (es) 2010-11-02
HRP20020924A2 (en) 2003-10-31
HU0204026D0 (en) 2003-01-28
IL161972A0 (en) 2005-11-20
IL161972A (en) 2009-06-15
BE1014078A6 (fr) 2003-03-04
AU2002302147B2 (en) 2005-01-20
ATE473006T1 (de) 2010-07-15
MXPA02011561A (es) 2005-07-13
SI1446126T1 (sl) 2010-10-29
BE1015217A5 (no) 2004-11-09
KR100979328B1 (ko) 2010-08-31

Similar Documents

Publication Publication Date Title
NO20042620L (no) Belagte partikulaere cefuroxim axetil-blandinger
JP2003524592A5 (no)
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
EE9900453A (et) Graanul, farmatseutiline doseerimisvorm, graanulite valmistamismeetod ja ravimiga kaetud graanulid
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
PT1309324E (pt) Derivados de anticonvulsivos uteis para o tratamento e prevencao do desenvolvimento de diabetes mellitus do tipo ii e da sindroma x
CA2272442A1 (en) Lozenge for the modified releasing of active substances in the gastrointestinal tract
AU2003223989A1 (en) System for orally administering active substances, vitamins and/or foodstuffs
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
RU2002131380A (ru) Фармацевтические композиции
TR200200112T2 (tr) Fosfat taşıma ihtibitörleri
HK1034674A1 (en) Orally administrable solid ribavirin dosage forms and process for making them.
GEP20063821B (en) Orodispersible pharmaceutical composition comprising perindopril
CA2377737A1 (en) Ultra-flexible gasket for liquid natural gas processing plants
CA2273277A1 (en) The use of oligosaccharides to increase the sweetness and improve the taste of an acesulfame-k/aspartame mixture
AU4655199A (en) Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
PT1073431E (pt) Utlizacao de antagonistas de nmda no tratamento da sindroma do intestino irritavel
RU93048335A (ru) Оральная лекарственная форма, материал для оболочки
AU2003256157A1 (en) Oral dosage forms of water insoluble drugs and methods of making the same
GB9910773D0 (en) Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
ITRM20000322A0 (it) Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
IT1320781B1 (it) Sistema per la preparazione di monostrati di particelle o molecole.
WO2002036774A3 (de) Derivate des humanen makrophagen migrations-inhibitions-faktors (mif) und deren verwendung in arzneimittelzubereitung und in screeningverfahren zur identifizierung von analoga, agonisten und antagonisten
関谷直人 et al. Thomas H. Troeger, Ten Strategies for Preaching in a Multi Media Culture (Nashville: Abingdon Press, 1996).

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

MM1K Lapsed by not paying the annual fees